Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
Analgesia and Pain Management01:25

Analgesia and Pain Management

3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.7K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.7K
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

257
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perianesthesia Nurses' Knowledge and Promotion of Safe Use, Storage, and Disposal of Opioids.

Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses·2019
Same author

Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2016
Same author

Safety concerns with long-term opioid use.

Expert opinion on drug safety·2016
Same author

Ultrasound-guided femoral nerve catheter for the treatment of refractory cancer pain.

Journal of palliative care·2014
Same author

Interventional treatment of refractory cancer pain.

Cancer journal (Sudbury, Mass.)·2013
Same author

Pharmacokinetic evaluation of hydrocodone/acetaminophen for pain management.

Journal of opioid management·2013

Related Experiment Video

Updated: May 5, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.2K

Update on extended-release opioids in pain management.

Paul Sloan1

  • 1University of Kentucky, Anesthesiology , 800 Rose St, Lexington, 40536 , USA paulsloan1956@yahoo.com.

Expert Opinion on Drug Delivery
|December 5, 2013
PubMed
Summary

Extended-release (ER) opioids aim to improve chronic pain management. This review examines the evidence for ER opioid benefits, including better pain relief and reduced addiction risk.

Area of Science:

  • Pharmacology
  • Pain Management
  • Drug Development

Background:

  • Opioids are primary treatments for chronic pain, including cancer and nonmalignant pain.
  • Immediate-release opioids offer analgesia but require frequent dosing.
  • Extended-release (ER) opioid formulations were developed to enhance pain management and patient outcomes.

Discussion:

  • ER opioids were designed to improve analgesia, reduce side effects, and increase convenience for chronic pain patients.
  • ER formulations aim to enhance compliance, improve sleep quality, and alleviate nighttime pain.
  • A key objective for modern ER opioid products is mitigating the risk of prescription opioid addiction.

Key Insights:

  • Evidence suggests ER opioid formulations have advanced in achieving improved analgesia and convenience.

More Related Videos

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.0K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

34.8K

Related Experiment Videos

Last Updated: May 5, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.2K
Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.0K
Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

34.8K
  • The impact of ER opioids on reducing side effects and improving patient compliance is a critical area of review.
  • Assessing the effectiveness of ER opioids in lowering the risk of opioid addiction is a primary focus.

    • Outlook:

    • Further research is needed to fully elucidate the long-term benefits and risks of ER opioid formulations.
    • Continued evaluation of ER opioid efficacy in diverse chronic pain populations is essential.
    • The development of safer and more effective ER opioid strategies remains a priority in pain management research.